GU Cancers 2023 | What to look forward to in urothelial cancer at ASCO GU 2023

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses what to look out for at the ASCO GU Cancers Symposium 2023, including data on whether adjuvant immunotherapy should be administered in the perioperative space. The current data suggests the use of adjuvant nivolumab only delays tumor recurrence, however, Dr Siefker-Radtke is hoping to see long-term data suggestive of cure or long-term benefit. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.